# Cleerly

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cleerly

- Industry: Healthcare IT
- Headquarters: Denver, US
- Website: www.cleerlyhealth.com
- Total disclosed funding: $314M
- Latest round: Series C (Nov 19, 2024)
- Investors on record: 16

## About

Founded in 2016 and based in New York, US, Cleerly, Inc. develops an AI-integrated digital platform that provides helpful insights and evaluations that help in preventing coronary artery disease. The company was formed from the research efforts of The Dalio Institute for Cardiovascular Imaging at the New York-Presbyterian Hospital and Weill Cornell Medicine, which later turned into Cleerly's technological progress. It was founded by Dr. James K. Min. In November 2024, Cleerly, Inc. raised USD 51.31 million in Series C funding co-led by Insight Partners and Battery Ventures, with participation from other unspecified investors. The company's product is an AI-integrated platform and solution that uses non-invasive AI-driven FDA-cleared technologies to identify the plaques that might cause coronary artery disease. For health professionals, the solution provides image analysis and data to help and support clinical diagnosis, prognostication, and the decision-making process. The platform also provides helpful insights to patients in order for them to understand the factors and prevention of coronary artery disease. The company's revenue is generated by the sales of its AI-integrated solution offered for imaging physicians, clinicians, and patients. The company intends to use the November 2024 funding to expand its team, expand access to its technology-enabled care pathway for heart disease, and conduct large-scale outcomes research.

## Funding rounds

- Series C, Nov 19, 2024, $51M — Battery Ventures, Insight Partners
- Series C, Jul 25, 2022, $223M — T Rowe Price, Novartis Venture Fund, LRVHealth, Mirae Asset Global Investments, New Leaf Venture Partners, Fidelity Investments, Piper Sandler, Breyer Capital, Sands Capital Alternatives, DigiTx Partners, Cigna Ventures, T. Rowe Price Investment Services, Vensana Capital
- Series B, Jun 21, 2021, $40M — LRVHealth, New Leaf Venture Partners, American College of Cardiology Foundation, DigiTx Partners, Cigna Ventures, Vensana Capital

## Investors

- LRVHealth (https://capitalatlas.ai/funds/lrvhealth) — Series B, Series C
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B, Series C
- American College of Cardiology Foundation — Series B
- DigiTx Partners (https://capitalatlas.ai/funds/digitx-partners) — Series B, Series C
- Cigna Ventures (https://capitalatlas.ai/funds/cigna-ventures) — Series B, Series C
- Vensana Capital (https://capitalatlas.ai/funds/vensana-capital) — Series B, Series C
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series C
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series C
- Mirae Asset Global Investments (https://capitalatlas.ai/funds/mirae-asset-global-investments) — Series C
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series C
- Piper Sandler (https://capitalatlas.ai/funds/piper-sandler) — Series C
- Breyer Capital (https://capitalatlas.ai/funds/breyer-capital) — Series C
- Sands Capital Alternatives (https://capitalatlas.ai/funds/sands-capital-alternatives) — Series C
- T. Rowe Price Investment Services — Series C
- Battery Ventures (https://capitalatlas.ai/funds/battery-ventures) — Series C
- Insight Partners (https://capitalatlas.ai/funds/insight-partners) — Series C